Biocryst制药公司预计将在2025年下半年实现季度正EPS和正现金流,并在2026年全年度实现EPS盈利和正现金流

财报速递
24 Feb
Biocryst制药公司预计将在2025年下半年实现季度正EPS和正现金流,并在2026年全年度实现EPS盈利和正现金流。

以上内容来自Benzinga Earnings专栏,原文如下:

Biocryst Pharmaceuticals Expects To Approach Quarterly Positive EPS And Positive Cash Flow In The Second Half Of 2025, And To Be Profitable On An EPS Basis, With Positive Cash Flow, For Full Year 2026

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10